Lipoprotein associated phospholipase A2 measurement

Sudhir K: Clinical review: Lipoprotein-associated phospholipase A2, a novel inflammatory biomarker and independent risk predictor for cardiovascular disease. J Clin Endocrinol Metab 2005; 90(5):3100-3105.

Koenig W, Khuseyinova N, Lowel H, et al: Lipoprotein-associated phospholipase A2 adds to risk prediction of incident coronary events by C-reactive protein in apparently healthy middle-aged men from the general population: results from the 14-year follow-up of a large cohort from southern Germany. Circulation 2004; 110(14):1903-1908.

Ballantyne CM, Hoogeveen RC, Bang H, et al: Lipoprotein-associated phospholipase A2, high-sensitivity C-reactive protein, and risk for incident coronary heart disease in middle-aged men and women in the Atherosclerosis Risk in Communities (ARIC) study. Circulation 2004; 109(7):837-842.

Brilakis ES, McConnell JP, Lennon RJ, et al: Association of lipoprotein-associated phospholipase A2 levels with coronary artery disease risk factors, angiographic coronary artery disease, and major adverse events at follow-up. Eur Heart J 2005; 26(2):137-144.

Oei HH, van der Meer IM, Hofman A, et al: Lipoprotein-associated phospholipase A2 activity is associated with risk of coronary heart disease and ischemic stroke: the Rotterdam Study. Circulation 2005; 111(5):570-575.

Ridker PM, Brown NJ, Vaughan DE, et al: Established and emerging plasma biomarkers in the prediction of first atherothrombotic events. Circulation 2004; 109(25 Suppl 1):IV6-IV19.

Packard CJ, O'Reilly DS, Caslake MJ, et al: Lipoprotein-associated phospholipase A2 as an independent predictor of coronary heart disease. West of Scotland Coronary Prevention Study Group. N Engl J Med 2000; 343(16):1148-1155.